Juan Carlos Torre Alonso1, Petra Díaz Del Campo Fontecha2, Raquel Almodóvar3, Juan D Cañete4, Carlos Montilla Morales5, Mireia Moreno6, Chamaida Plasencia-Rodríguez7, Julio Ramírez García8, Rubén Queiro9. 1. Unidad de Reumatología, Hospital Monte Naranco y Universidad de Oviedo, Oviedo, España. 2. Unidad de Investigación, Sociedad Española de Reumatología, Madrid, España. 3. Unidad de Reumatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España. 4. Unidad de Artritis, Servicio de Reumatología, Hospital Clínic, Barcelona, España. 5. Servicio de Reumatología, Hospital Clínico Universitario de Salamanca, Salamanca, España. 6. Servicio de Reumatología, Parc Taulí Hospital Universitari, Sabadell, Barcelona, España. 7. Servicio de Reumatología, Hospital Universitario La Paz, IdiPaz, Madrid, España. 8. Unidad de Artritis, Servicio de Reumatología, IDIBAPS y Hospital Clínic, Barcelona, España. 9. Sección de Reumatología, Hospital Universitario Central de Asturias, Oviedo, España. Electronic address: rubenque7@yahoo.es.
Abstract
OBJECTIVE: The main purpose of this recommendation statement is to provide clinicians with the best available evidence and the best opinion agreed upon by the panelists for a rational use of synthetic disease modifying antirheumatic drugs (DMARDs) and biologicals in psoriatic arthritis (PsA) patients. The present document also focuses on important aspects in the management of PsA, such as early diagnosis, therapeutic objectives, comorbidities and optimization of treatment. METHODS: The recommendations were agreed by consensus by a panel of 8 expert rheumatologists, previously selected by the Spanish Society of Rheumatology (SER) through an open call. The phases of the work were: identification of key areas for updating the previous consensus, analysis and synthesis of scientific evidence (modified Oxford system, Centre for Evidence-based Medicine, 2009) and formulation of recommendations based on this evidence and by consensus techniques. RESULTS: Seventeen recommendations were issued for the treatment of PsA patients. Six of them were of general nature, ranging from the early diagnosis and treatment to the importance of assessing comorbidities. The other 11 were focused on the indications for DMARDs and biological therapy in the distinct clinical forms of the disease. Likewise, the situation of failure of the first biological is addressed and treatment algorithms and a table with the different biological therapies are also included. CONCLUSIONS: We present the update of SER recommendations for the treatment of PsA with DMARDs and biologics.
OBJECTIVE: The main purpose of this recommendation statement is to provide clinicians with the best available evidence and the best opinion agreed upon by the panelists for a rational use of synthetic disease modifying antirheumatic drugs (DMARDs) and biologicals in psoriatic arthritis (PsA) patients. The present document also focuses on important aspects in the management of PsA, such as early diagnosis, therapeutic objectives, comorbidities and optimization of treatment. METHODS: The recommendations were agreed by consensus by a panel of 8 expert rheumatologists, previously selected by the Spanish Society of Rheumatology (SER) through an open call. The phases of the work were: identification of key areas for updating the previous consensus, analysis and synthesis of scientific evidence (modified Oxford system, Centre for Evidence-based Medicine, 2009) and formulation of recommendations based on this evidence and by consensus techniques. RESULTS: Seventeen recommendations were issued for the treatment of PsA patients. Six of them were of general nature, ranging from the early diagnosis and treatment to the importance of assessing comorbidities. The other 11 were focused on the indications for DMARDs and biological therapy in the distinct clinical forms of the disease. Likewise, the situation of failure of the first biological is addressed and treatment algorithms and a table with the different biological therapies are also included. CONCLUSIONS: We present the update of SER recommendations for the treatment of PsA with DMARDs and biologics.
Authors: Manuel José Moreno-Ramos; Carlos Sanchez-Piedra; Olga Martínez-González; Carlos Rodríguez-Lozano; Carolina Pérez-Garcia; Mercedes Freire; Cristina Campos; Rafael Cáliz-Caliz; Jerusalem Calvo; Juan María Blanco-Madrigal; Ana Pérez-Gómez; María José Moreno-Martínez; Luis Linares; Fernando Sánchez-Alonso; Carlos Sastré; Isabel Castrejón Journal: Rheumatol Ther Date: 2022-04-25